普通人群肝脏受控衰减参数的多元回归分析*

doi:10.3969/j.issn.1672-5069.2014.03.018

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (3): 291-295.doi: 10.3969/j.issn.1672-5069.2014.03.018

普通人群肝脏受控衰减参数的多元回归分析^*

卢加发, 潘勤, 陈光榆, 沈峰, 章瑞南, 朱婵艳, 陈一铭, 张舒宜, 吴佳瑜, 范建高

200092上海市上海交通大学医学院附属新华医院消化内科(卢加发,潘勤,沈峰,章瑞南,朱婵艳,陈一铭,张舒宜,吴佳瑜,范建高); 临床流行病学研究中心(陈光榆)

收稿日期:2013-11-01 出版日期:2014-06-30 发布日期:2016-04-11
作者简介:卢加发,男,30岁,硕士研究生,医师。主要从事脂肪肝研究。E-mail：lujia120@hotmail.com
基金资助:
国家重点基础研究发展计划(973计划)项目（2012CB517501); 上海市科委创新行动计划（10411956300）; 中国肝炎防治基金会王宝恩肝纤维化研究基金资助项目(XJS20120501); 上海交通大学医学院附属新华医院院长基金项目(12QYJ05)

Multivariable regression analysis of controlled attenuation parameter of liver by FibroScan in healthy individuals

Lu Jiafa,Pan Qin,Chen Guangyu

Department of Gastroenterology,Xinhua Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200092,China

Received:2013-11-01 Online:2014-06-30 Published:2016-04-11

摘要/Abstract

摘要： 目的探讨影响普通人群肝脏受控衰减参数的相关因素。方法使用FibroScan○R-520诊断仪检测208例健康体检者肝脏受控衰减参数（ CAP值）,同时获取受试者的主要生化指标和性别、年龄、体质量指数、腰高比、腰臀比,对其进行多元线性回归分析和偏最小二乘回归分析,建立回归方程。结果多元线性回归分析显示,CAP值与体质量指数、腰臀比和年龄呈显著性相关,其标准回归系数分别为：体质量指数,β=0.2538,P=0.0007;腰臀比,β=0.1781,P=0.0158;年龄,β=0.1935,P=0.0022;通过多元回归分析和偏最小二乘回归建立的模型分别为：CAP=-137.70+9.40×甘油三脂+5.40×体质量指数+176.34×腰臀比+1.60×年龄,改良的CAP=-135.23+11.57×甘油三脂+4.82×体质量指数+212.81×腰臀比+1.12×年龄。结论普通人群CAP正常值范围受体质量指数、腰臀比和年龄的影响,改良的回归模型能更好地反映肝脏CAP值。

关键词: 肝脏脂肪变, 瞬时弹性记录仪, 受控衰减参数, 回归方程

Abstract: Objective To explore the related factors of controlled attenuation parameter （CAP） of liver obtained by FibroScan examination in healthy individuals. Methods The CAP was obtained by FibroScan in208healthy persons, and the main biochemical indexes, gender, age, body mass index （BMI）, waist-hip ratio （WHR）, waist-height ratio were collected at the same time, and the relationship between CAP value, these common indicators was analyzed. Results Multiple linear regression analysis showed that CAP value was significantly correlated with BMI, WHR, age （for BMI, β=0.280, P=0.0002;for WHR, β=0.206, P=0.0059;for age, β=0.192, P=0.0022）;And the regression equation established after multiple linear regression analysis, partial least squares regression were CAP=-137.70+9.40*TG+5.40*BMI+176.34*WHR+1.60*age, the adjusted CAP=-92.11+10.67*TG-10.25*HDL+4.45*BMI+196.25*WHR+1.03*age. Conclusions The range of CAP value is affected by BMI, WHR, and age in the general population, the adjusted regression equation is more better to predict the CAP value of the liver

Key words: Liver steatosis, FibroScan, Controlled attenuation parameter, Regression equation

卢加发, 潘勤, 陈光榆, 沈峰, 章瑞南, 朱婵艳, 陈一铭, 张舒宜, 吴佳瑜, 范建高. 普通人群肝脏受控衰减参数的多元回归分析^*[J]. 实用肝脏病杂志, 2014, 17(3): 291-295.

Lu Jiafa,Pan Qin,Chen Guangyu. Multivariable regression analysis of controlled attenuation parameter of liver by FibroScan in healthy individuals[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 291-295.

参考文献

[1] Dowman JK,Tomlinson JW,Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther,2011,33（5）:525-540.
[2] Ratziu V,Charlotte F,Heurtier A,et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology,2005,128（7）:1898-1906.
[3] Regev A,Berho M,Jeffers LJ,et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol, 2002,97:2614-2618.
[4] Saadeh S,Younossi ZM,Remer EM,et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology,2002,123（3）: 745-750.
[5] Schwenzer NF,Springer F,Schraml C,et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol,2009,51（3）:433-445.
[6] Sasso M,Beaugrand M,de Ledinghen V,et al. Controlled attenuation parameter （CAP）:a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol,2010,36（11）:1825-1835.
[7] De Ledinghen V,Vergniol J,Foucher J,et al. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter （CAP） and transient elastography. Liver Int,2012,32（6）:911-918.
[8] Myers RP,Pollett A,Kirsch R,et al. Controlled attenuation parameter （CAP）:a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int,2012,32（6）:902-910.
[9] Sasso M,Tengher-Barna I,Ziol M,et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan:validation in chronic hepatitis. C. J Viral Hepat,2012,19（4）:244-253.
[10] Kumar M,Rastogi A,Singh T,et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis:Does etiology affect performance J Gastroenterol Hepatol,2013,28（7）:1194-1201.
[11] Andersen ES,Christensen PB,Weis N. Transient elastography for liver fibrosis diagnosis. Eur J Intern Med,2009,20（4）：339-342.
[12] Wong GLH.Transient elastography:Kill two birds with one stone World J Hepatol,2013,5（5）:264-274.
[13] Degos F,Perez P,Roche P,et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis:A multicenter prospective study （the FIBROSTIC study）. J Hepatol,2010,53（6）:1013-1021.
[14] 沈峰,潘勤,范建高,等. FibroScan:实施受控衰减参数评价脂肪肝的影响因素及重复性分析. 实用肝脏病杂志,2013,16（1）:59-62.
[15] Chon YE,Jung KS,Kim SU,et al. Controlled attenuation parameter （CAP） for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int, 2013,34（1）:102-109.
[16] Masaki K,Takaki S,Hyogo H,et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res,2013,43（11）:1182-1189.
[17] Xu C,Yu C,Ma H,et al. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population:the Zhejiang Zhenhai Study. Am J Gastroenterol,2013,108（8）:1299-1304.
[18] Nascimbeni F,Pais R,Bellentani S,et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol,2013,59（4）:859-871.
[19] 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议.实用肝脏病杂志,2013,16（3）:207-209.

普通人群肝脏受控衰减参数的多元回归分析^*

Multivariable regression analysis of controlled attenuation parameter of liver by FibroScan in healthy individuals

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价

[1]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[2]	董雪莲, 张文均. 肝脏受控衰减参数检测早期无创发现代谢综合征人群价值分析^*[J]. 实用肝脏病杂志, 2018, 21(6): 868-871.
[3]	王倩,郭萍. Fibroscan联合人体测量学指标诊断非酒精性脂肪性肝病效能分析[J]. 实用肝脏病杂志, 2017, 20(6): 754-755.
[4]	孙长贵，曾静，孙婉璐，陈光榆，潘勤，范建高. 非酒精性脂肪性肝病患者估算的肾小球滤过率的变化及其影响因素分析*[J]. 实用肝脏病杂志, 2017, 20(2): 165-170.
[5]	陈光榆, 潘勤, 沈峰, 卢加发, 章瑞南, 朱婵艳, 孙婉璐, 曾静, 吴佳瑜, 范建高. 进食对Fibroscan检测肝脏受控衰减参数的影响^*[J]. 实用肝脏病杂志, 2016, 19(5): 553-556.
[6]	曾静, 陈光榆, 潘勤, 孙婉璐, 顾立飞, 颜士岩, 孙超, 徐正婕, 范建高. FibroTouch检测脾脏与肝脏受控衰减参数的相关性及影响因素分析^*[J]. 实用肝脏病杂志, 2016, 19(4): 445-450.
[7]	杨硕, 吕栋, 王天懿, 张龙友, 徐有青. FibroTouch^®脂肪衰减参数对非酒精性脂肪性肝病患者肝脏脂肪变程度的诊断价值*[J]. 实用肝脏病杂志, 2016, 19(1): 50-54.
[8]	王文睿，杨岚岚，贾胜男，金珍婧. FibroTouch受控衰减参数评价非酒精性脂肪性肝病相关因素分析^*[J]. 实用肝脏病杂志, 2015, 18(4): 367-370.
[9]	卢加发, 刘文斌, 潘勤, 陈光榆, 沈峰, 章瑞南, 朱婵艳, 陈一铭, 张舒宜, 吴佳瑜, 范建高. 健康体检成人FibroScan检测肝脏硬度值与受控衰减参数的相关分析^*[J]. 实用肝脏病杂志, 2014, 17(5): 484-489.